Published in J Am Coll Cardiol on January 01, 2000
Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol (2008) 1.38
Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J (2011) 1.36
Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care (2010) 1.18
Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag (2006) 0.99
Peripheral airway obstruction in primary pulmonary hypertension. Thorax (2002) 0.95
Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag (2009) 0.87
Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir Res (2005) 0.86
Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag (2009) 0.85
Pulmonary hypertension in infants with bronchopulmonary dysplasia. Korean J Pediatr (2010) 0.83
Pharmacologic management of perioperative pulmonary hypertension. J Cardiovasc Pharmacol (2014) 0.81
Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart (2001) 0.79
Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension. Exp Biol Med (Maywood) (2014) 0.78
Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure. J Card Fail (2011) 0.78
Improvement in right ventricular function during reversibility testing in pulmonary arterial hypertension: a case report. Cardiovasc Ultrasound (2009) 0.78
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension. Ann Thorac Med (2014) 0.77
Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension. Pulm Circ (2015) 0.75
Calculation of resistance to pulmonary perfusion. J Am Coll Cardiol (2000) 0.75
Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol (2016) 0.75
The limits of oral therapy in pulmonary arterial hypertension management. Ther Clin Risk Manag (2015) 0.75
Accessing genetic information with high-density DNA arrays. Science (1996) 13.89
Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med (1998) 7.34
Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci (1997) 3.61
The molecular architecture of focal adhesions. Annu Rev Cell Dev Biol (1995) 3.41
Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci (2000) 3.40
Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J (2009) 3.31
Sildenafil treatment for portopulmonary hypertension. Eur Respir J (2006) 2.58
N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol (2001) 2.57
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med (2000) 2.55
Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J (2010) 2.51
Analysis of neurogenesis and programmed cell death reveals a self-renewing capacity in the adult rat brain. Neurosci Lett (2000) 2.22
Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem (2000) 2.19
Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med (2000) 2.18
Neoalveolarisation contributes to compensatory lung growth following pneumonectomy in mice. Eur Respir J (2007) 2.11
[Number of patients with chronic dyspnea in three German specialist practices]. Pneumologie (2012) 2.08
Leaf disc transformation of cultivated tomato (L. esculentum) using Agrobacterium tumefaciens. Plant Cell Rep (1986) 2.05
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J (2009) 2.04
[The diagnosis of primary pulmonary hypertension]. Dtsch Med Wochenschr (1993) 2.03
Laparoscopic sleeve gastrectomy as a weight reduction strategy in obese patients after kidney transplantation. Am J Transplant (2014) 2.02
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J (2004) 2.02
Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J (2008) 1.97
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.95
Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol (2001) 1.85
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J (2006) 1.84
Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med (1996) 1.79
Pulmonary vascular resistances during exercise in normal subjects: a systematic review. Eur Respir J (2011) 1.77
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet (2003) 1.76
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet (1993) 1.74
Mapping a cave fish genome: polygenic systems and regressive evolution. J Hered (2002) 1.71
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J (2005) 1.71
The dorsolateral, suboccipital, transcondylar approach to the lower clivus and anterior portion of the craniocervical junction. Neurosurgery (1991) 1.67
Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation (2001) 1.64
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J (2008) 1.62
Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med (1999) 1.61
Bacterial exotoxins and endothelial permeability for water and albumin in vitro. Am J Physiol (1988) 1.61
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther (2010) 1.57
Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol (1985) 1.57
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med (2000) 1.57
Pulmonary hypertension after splenectomy? Ann Intern Med (1999) 1.55
Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2000) 1.54
Aerosolized surfactant inhibits acetylcholine-induced airway obstruction in rats. Eur Respir J (1997) 1.54
Intraparenchymal infusions of 192 IgG-saporin: development of a method for selective and discrete lesioning of cholinergic basal forebrain nuclei. J Neurosci Methods (1999) 1.52
Factors influencing breath condensate volume. Pneumologie (2001) 1.51
Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J (2008) 1.48
[Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. Pneumologie (2002) 1.48
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J (2010) 1.47
[Recommendations of the German Respiratory League for treatment of patients with chronic obstructive bronchitis and pulmonary emphysema]. Med Klin (Munich) (1995) 1.46
Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation (2000) 1.46
Genetic divergence between cave and surface populations of Astyanax in Mexico (Characidae, Teleostei). Mol Ecol (2003) 1.45
[Recommendations of the German Respiratory Tract League on asthma management of adults and children. The German Respiratory Tract League]. Med Klin (Munich) (1994) 1.45
Location and type of mutation in the LIS1 gene do not predict phenotypic severity. Neurology (2007) 1.45
Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol (1985) (1985) 1.44
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J (2009) 1.44
Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. J Clin Invest (1984) 1.43
Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med (2001) 1.43
Functional imaging in PNH caused by a new FilaminA mutation. Neurology (2004) 1.43
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med (1996) 1.42
Noninvasive assessment of regional cardiac adenosine using positron emission tomography. J Nucl Med (1992) 1.41
Characterisation of post-pneumonectomy lung growth in adult mice. Eur Respir J (2004) 1.39
[Correlation of TEI Index and invasive parameters of rightheart function in PAH]. Pneumologie (2004) 1.38
Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release (2005) 1.38
The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies. Am J Respir Crit Care Med (2000) 1.36
ARX mutations in X-linked lissencephaly with abnormal genitalia. Neurology (2003) 1.36
Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J (1996) 1.35
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J (2002) 1.35
Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis (2010) 1.35
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost (2000) 1.33
Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. J Immunol (2000) 1.32
Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun (1987) 1.30
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J (2002) 1.27
Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax (2000) 1.27
Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis (1989) 1.27
Frequency and phenotype of SPG11 and SPG15 in complicated hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry (2009) 1.26
Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. Eur Respir J (2008) 1.24
Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res (2001) 1.23
Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol (1997) 1.23
Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? Am J Physiol Lung Cell Mol Physiol (2000) 1.22
Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice. Am J Respir Crit Care Med (2001) 1.21
"Motor circuit" gray matter changes in idiopathic cervical dystonia. Neurology (2003) 1.20